Twice daily GSP301, a fixed-dose nasal spray containing 665µg olopatadine hydrochloride and 25µg mometasone furoate, offers a rapid onset of action, is well tolerated, and is associated with noticeable improvements in ocular symptoms in patients with seasonal allergic rhinitis.
Certain intranasal corticosteroids (INCS) may place patients with allergic rhinitis at a higher risk for epistaxis, according to a study published in Otolaryngology-Head and Neck Surgery.
Tivic Health Systems announced that ClearUP Sinus Pain Relief has been cleared by the Food and Drug Administration (FDA) for the treatment of sinus pain due to allergic rhinitis, or hay fever, in adults aged ≥18 years.
Patients who received a fixed-dose combination nasal spray showed significantly improved Physician-assessed Nasal Symptom Scores compared with those who received placebo.
Adverse drug reactions from the 300IR 5-grass pollen tablet occurred in approximately half of patients but typically resolved within a week of treatment.
Montelukast plus levocetirizine demonstrated a significant reduction in mean daytime nasal symptom scores compared with montelukast monotherapy.
According to the report, the patient complained of a non-productive cough, accumulation of mucus, and post-nasal drip and requested a thorough assessment of her medical conditions.
The NDA included safety and efficacy data from 2 randomized, multicenter, double-blind, placebo-controlled trials in patients aged ≥12 years with seasonal allergic rhinitis (N=2352).
The recalled nasal decongestant has a Lot number of 173089J and an expiration date of 09/19; it is packaged in 0.5 fluid ounce bottles.
The researchers found that the budesonide group had a mean score on the Sino-Nasal Outcome Test (SNOT-22) that was 7 points better (95% confidence interval, −2 to 16) than the control group.
